E. Carmack Holmes, Director at CYTORI THERAPEUTICS, INC. (CYTX), sold 20,000 shares at $9.16 ($181K) on 2010-01-20, disclosed to the SEC on 2010-01-21.
Scheduled sale ($181k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.00 | 3,900 | $35K | 19.4% |
| 2 | $9.01 | 1,000 | $9K | 5.0% |
| 3 | $9.04 | 800 | $7K | 4.0% |
| 4 | $9.05 | 3,400 | $31K | 17.0% |
| 5 | $9.06 | 2,200 | $20K | 11.0% |
| 6 | $9.07 | 2,300 |
| $21K |
| 11.5% |
| 7 | $9.08 | 1,300 | $12K | 6.5% |
| 8 | $9.08 | 100 | $908 | 0.5% |
| 9 | $9.09 | 500 | $5K | 2.5% |
| 10 | $9.10 | 400 | $4K | 2.0% |
| 11 | $9.12 | 800 | $7K | 4.0% |
| 12 | $9.13 | 1,300 | $12K | 6.5% |
| 13 | $9.14 | 1,500 | $14K | 7.6% |
| 14 | $9.16 | 500 | $5K | 2.5% |
| Total | $9.06 avg | 20,000 | $181K | 100% |